2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow HER-2 Gene Amplification: new trials by email Literature Review of HER-2 Gene Amplification trials Research Report on HER-2 Gene Amplification
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111 - HER-2 Gene Amplification | Phase 1 | Completed | Merrimack Pharmaceuticals | 100 | 2011-01-01 | 2015-12-16 |
Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Mucoepidermoid (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Laryngeal Neoplasms (1) · Lip Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Mouth Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Adenocarcinoma (1) · Adnexal Diseases (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Breast Diseases (1) · Carcinoma (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1)
Capecitabine (1) · Cisplatin (1) · Docetaxel (1) · Lapatinib (1) · MM-111 (1) · Paclitaxel (1) · Trastuzumab (1)
Klus Pharma Inc. (1) · Merrimack Pharmaceuticals (1)
United States (2)